J.W. Cole Advisors Inc. Invests $366,000 in Axon Enterprise, Inc. (NASDAQ:AXON)

J.W. Cole Advisors Inc. acquired a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,243 shares of the biotechnology company’s stock, valued at approximately $366,000.

A number of other large investors also recently modified their holdings of the company. OV Management LLC grew its position in shares of Axon Enterprise by 27.1% in the 2nd quarter. OV Management LLC now owns 3,367 shares of the biotechnology company’s stock valued at $991,000 after buying an additional 717 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Axon Enterprise by 12.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 79,908 shares of the biotechnology company’s stock worth $23,512,000 after purchasing an additional 8,575 shares during the period. Thoroughbred Financial Services LLC acquired a new stake in Axon Enterprise during the 2nd quarter worth $368,000. CoreCap Advisors LLC acquired a new stake in shares of Axon Enterprise in the 2nd quarter worth $592,000. Finally, Federated Hermes Inc. lifted its stake in shares of Axon Enterprise by 14.5% in the 2nd quarter. Federated Hermes Inc. now owns 234,185 shares of the biotechnology company’s stock worth $68,907,000 after acquiring an additional 29,680 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AXON has been the subject of several recent analyst reports. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price for the company. Craig Hallum raised their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Bank of America started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective for the company. Northland Securities raised their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Finally, Barclays raised their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $383.01 on Thursday. The company has a market cap of $28.90 billion, a PE ratio of 111.99, a price-to-earnings-growth ratio of 10.30 and a beta of 0.94. Axon Enterprise, Inc. has a 12 month low of $189.12 and a 12 month high of $387.61. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a 50-day simple moving average of $342.26 and a 200-day simple moving average of $315.72.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same period last year, the company earned $0.80 earnings per share. The company’s quarterly revenue was up 34.5% on a year-over-year basis. On average, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the sale, the director now directly owns 27,259 shares of the company’s stock, valued at $10,385,406.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the sale, the director now directly owns 27,259 shares of the company’s stock, valued at $10,385,406.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brittany Bagley sold 4,338 shares of Axon Enterprise stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the transaction, the chief financial officer now directly owns 98,825 shares in the company, valued at $37,449,733.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 317,981 shares of company stock valued at $115,662,734. Insiders own 6.10% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.